



26<sup>th</sup> ASIA-PACIFIC PROSTATE CANCER CONFERENCE

# APCC26

Melbourne Convention & Exhibition Centre, Australia | AUGUST 13-15

Together In Discovery & Care



## ADVANCES IN FOCAL THERAPY FOR PROSTATE CANCER: FROM PATIENT SELECTION TO CLINICAL OUTCOMES



**THURSDAY**  
**13 August, 2026**  
1330 - 1730

**Focal therapy is emerging as an important treatment option for selected men with localised prostate cancer, offering the potential for oncological control while minimising treatment-related morbidity.**

As the landscape of prostate cancer treatment evolves, focal therapy is gaining increasing attention as a precision-based approach for selected patients with localised disease.

This program will bring together leading clinicians to review the latest evidence supporting focal therapy, discuss advances in imaging such as MRI and PSMA for patient selection and follow-up, and examine the clinical decision-making involved in treating higher-grade disease and managing recurrence. We will explore the evolving evidence base, advances in imaging for patient selection, and the role of multidisciplinary decision-making in focal therapy.

Through expert presentations and multidisciplinary case discussions, participants will gain practical insights into Emerging focal treatment modalities and the future direction of focal therapy in prostate cancer care

### FACULTY



**Prof Jonathon Coleman,**  
Memorial Sloan Kettering Cancer Center, United States

**A/Prof Anna Lantz,**  
Karolinska Comprehensive Cancer Center, Sweden



**A/Prof Kara Watts,**  
Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, United States



### WORKSHOP CHAIRS

Associate Professor John Yaxley  
Dr Nick Mehan

<b>1330-1345</b>	<b>Welcome</b>
1345-1400	<b>The emerging role of focal therapy for treatment of localised prostate cancer – summary of the evidence</b> A/Prof Anna Lantz, Karolinska Comprehensive Cancer Center, Sweden
1400-1415	<b>Imaging for focal therapy and case selection</b> A/Prof Kara Watts, Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, United States
1415-1430	<b>Focal therapy for high grade prostate cancer – why not?</b> Prof Phillip Stricker, St Vincent's Prostate Cancer Research Centre, Sydney
1430-1445	<b>Redefining clinically significant prostate cancer, what contralateral lobe volume or grade is a contraindication to focal therapy?</b> A/Prof Kara Watts, Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, United States
1445-1500	<b>Local recurrence after focal therapy – repeat focal ablation or whole gland therapy: indications and outcomes</b> Prof Jonathon Coleman, Memorial Sloan Kettering Cancer Center, United States
<b>1500-1530</b>	<b>Afternoon Tea</b>
1530-1545	<b>Follow up protocol for patients after focal therapy, striving for consensus</b> Prof Mark Frydenberg, Australian Urology Associates, Melbourne
1545-1600	<b>Indications and outcomes of focal LDR prostate brachytherapy</b> A/Prof Jeremy Grummet, Alfred Health, Melbourne
1600-1615	<b>Focal irreversible electroporation: oncological and quality of life outcomes</b> Prof Jonathon Coleman, Memorial Sloan Kettering Cancer Center, United States
1615-1630	<b>Early outcomes of focal laser ablation for localised prostate cancer</b> Dr Jonathan Kam, Nepean Private Hospital, Sydney
1630-1715	<b>MDT case presentations chaired by</b> Dr Nick Mehan Prof Jonathon Coleman, A/Prof Anna Lantz, A/Prof Kara Watts, Prof Phillip Stricker
<b>1730</b>	<b>Conclude</b>

*[Program correct at time of publication]*

### FIND OUT MORE

Scan the QR code to learn more about the APCC26 workshops.



**For a 10% discount use code UROLOGY10**

Proudly sponsored by

